NCT01536574View on ClinicalTrials.gov

Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528

PHASE3CompletedINTERVENTIONAL
Enrollment

295

Participants

Timeline

Start Date

September 2, 2010

Primary Completion Date

March 1, 2012

Study Completion Date

March 28, 2012

Conditions
Parkinson Disease
Interventions
DRUG

Requip PR

Eligible patients will be dispensed medication to uptitrate their REQUIP PR dose (2, 4, 6, 8mg respectively) during the first 4 weeks of treatment. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control.

Trial Locations (18)

100034

GSK Investigational Site, Beijing

100050

GSK Investigational Site, Beijing

100053

GSK Investigational Site, Beijing

100730

GSK Investigational Site, Beijing

100853

GSK Investigational Site, Beijing

200025

GSK Investigational Site, Shanghai

200032

GSK Investigational Site, Shanghai

200040

GSK Investigational Site, Shanghai

215004

GSK Investigational Site, Suzhou

300052

GSK Investigational Site, Tianjin

310009

GSK Investigational Site, Hangzhou

430022

GSK Investigational Site, Wuhan

510120

GSK Investigational Site, Guangzhou

610041

GSK Investigational Site, Chengdu

610072

GSK Investigational Site, Chengdu

650032

GSK Investigational Site, Kunming

650101

GSK Investigational Site, Kunming

710061

GSK Investigational Site, Xi'an

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01536574 - Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528 | Biotech Hunter | Biotech Hunter